Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Amgevita

    - PMLiVE

    Amgen reports positive results from landmark cardiovascular study

    The study found significant reductions of major cardiovascular events in high-risk adults following treatment

    - PMLiVE

    Amgen commits $650m to US manufacturing expansion

    The investment is expected to generate up to 750 new jobs

    - PMLiVE

    Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis

    The phase 3 study included around 2,600 patients

    - PMLiVE

    Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

    Almost one million new cases of gastric cancer are diagnosed globally every year

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    - PMLiVE

    FDA grants interchangeable designation to Celltrion’s Humira biosimilar Yuflyma

    The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

    - PMLiVE

    Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD

    Immunoglobulin G4-related disease affects approximately 20,000 people in the US

    - PMLiVE

    Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study

    Regulatory submissions are expected to be complete in the first half of this year

    - PMLiVE

    Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis

    The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide

    - PMLiVE

    Amgen’s Blincyto recommended by NICE for new adult leukaemia indication

    Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment

    EU flag

    EC approves Biocon’s Stelara biosimilar Yesintek for inflammatory diseases

    The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

    - PMLiVE

    Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication

    B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links